Skip to main content
SpringerLink
Log in

Exercise Recommendations in Pediatric HCM: Variation and Influence of Provider Characteristics

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Pediatric Hypertrophic Cardiomyopathy (HCM) is associated with sudden cardiac death (SCD) that can be related to physical activity. Without pediatric specific guidelines, recommendations for activity restriction may be varied. Therefore, our aim is to determine the current practice and variability surrounding exercise clearance recommendations (ER) in pediatric HCM referral centers as well as provider and patient characteristics that influence them. We designed a survey that was distributed to the Pediatric Heart Transplant Study (PHTS) providers and members of the Pediatric and Adult Congenital Electrophysiology Society (PACES) querying provider demographics and patient variables from 2 patient vignettes. The study is a multicenter survey of current practice of specialized providers caring for pediatric HCM patients. Survey of PHTS and PACES providers via email to the respective listservs with a response rate of 28% and 91 overall completing the entire survey after self-identifying as providers for pediatric HCM patients at their center. ER varies for pediatric HCM and is associated with provider training background as well as personal and professional history. Of the 91 providers who completed the survey, 42% (N = 38) trained in pediatric electrophysiology (EP), and 40% (N = 36) in pediatric heart failure (HF). Responses varied and only 53% of providers cleared for mild to moderate activity for the patient in Vignette 1, which is more in line with recent published adult guidelines. ER in both vignettes was significantly associated with type of training background. EP providers were more likely to recommend no restriction (27.8% vs 5.9%) than HF providers even when controlling for provider age and time out of training. Syncope with exercise was deemed “Most Important” by 81% of providers when making ER. ER for pediatric HCM are variable and the majority of providers make ER outside of previously published adult guidelines. Furthermore, ER are influenced by provider background and experience. Further study is needed for risks and benefits of physical activity in this population to inform the development of pediatric specific guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Alexander PMA, Nugent AW, Daubeney P et al (2018) Long-term outcomes of hypertrophic cardiomyopathy diagnosed during childhood: results from a national population-based study. Circulation 138:29–36. https://doi.org/10.1161/CIRCULATIONAHA.117.028895

    Article  PubMed  Google Scholar 

  2. Teare D (1958) Asymmetrical hypertrophy of the heart in young adults. Br Hear J 20(1):1–8

    Article  CAS  Google Scholar 

  3. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS (2014) Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am Coll Cardiol 64(1):83–99. https://doi.org/10.1016/j.jacc.2014.05.003

    Article  PubMed  Google Scholar 

  4. Thompson T, Connell V, Wallace J et al (2016) A prospective study of sudden cardiac death among children and young adults. N Engl J Med 374(25):2441–2452. https://doi.org/10.1056/NEJMoa1510687

    Article  PubMed  Google Scholar 

  5. Kaski JP, Esteban M, Lowe M et al (2007) Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart 93:372–374. https://doi.org/10.1136/hrt.2006.094730

    Article  PubMed  Google Scholar 

  6. Maron BJ, Spirito P, Ackerman MJ et al (2013) Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 61:1527–1535. https://doi.org/10.1016/j.jacc.2013.01.037

    Article  PubMed  Google Scholar 

  7. Balaji S, Dilorenzo MP, Fish FA et al (2019) Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: an international multicenter study. Heart Rhythm 16:1462–1467. https://doi.org/10.1016/j.hrthm.2019.04.040

    Article  PubMed  Google Scholar 

  8. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO (2009) Sudden deaths in young competitive athlete: analysis of 1866 deaths in the United States, 1980–2006. Circulation 119:1085–1092. https://doi.org/10.1161/CIRCULATIONAHA.108.804617

    Article  PubMed  Google Scholar 

  9. Maron BJ, Haas TS, Ahluwalia A, Murphy CJ, Garberich RF (2016) Demographics and epidemiology of sudden deaths in young competitive athletes : from the united states national registry. Am J Med 129(11):1170–1177. https://doi.org/10.1016/j.amjmed.2016.02.031

    Article  PubMed  Google Scholar 

  10. Ullal AJ, Abdelfattah RS, Ashley EA, Froelicher VF (2016) Hypertrophic cardiomyopathy as a cause of sudden cardiac death in the young: a meta-analysis. Am J Med 129(5):486-496.e2. https://doi.org/10.1016/j.amjmed.2015.12.027

    Article  PubMed  Google Scholar 

  11. Maron BJ, Haas TS, Murphy CJ, Ahluwalia A, Rutten-ramos S (2014) Incidence and causes of sudden death in US college athletes. J Am Coll Cardiol 63(16):1636–1643. https://doi.org/10.1016/j.jacc.2014.01.041

    Article  PubMed  Google Scholar 

  12. Maron BJ, Chaitman BR, Ackerman MJ et al (2004) Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 109(22):2807–2816. https://doi.org/10.1161/01.CIR.0000128363.85581.E1

    Article  PubMed  Google Scholar 

  13. Burke MA, Day SM, Deswal A et al (2020) Circulation AHA / ACC CLINICAL PRACTICE GUIDELINE 2020 AHA / ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy association joint committee on clinical practice guidelines. Circulation 142:1–74. https://doi.org/10.1161/CIR.0000000000000937

    Article  Google Scholar 

  14. Aro A, Nair S, Reinier K et al (2017) Population burden of sudden death associated with hypertrophic cardiomyopathy. Circulation 136:1665–1667. https://doi.org/10.1161/CIRCULATIONAHA.117.030616

    Article  PubMed  PubMed Central  Google Scholar 

  15. Mathew J, Zahavich L, Lafreniere-Roula M et al (2018) Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy. Clin Genet 93:310–319. https://doi.org/10.1111/cge.13157

    Article  CAS  PubMed  Google Scholar 

  16. Mahony CO, Akhtar MM, Anastasiou Z et al (2019) Effectiveness of the 2014 European society of cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart 105:623–631. https://doi.org/10.1136/heartjnl-2018-313700

    Article  Google Scholar 

  17. Miron A, Lafreniere-Roula M, Fan CS et al. 2020 A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. Circulation. ;10.

  18. Norrish G, Ding T, Field E et al (2020) Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids). JAMA Cardiol 4(9):918–927. https://doi.org/10.1001/jamacardio.2019.2861

    Article  Google Scholar 

  19. Mahony CO, Jichi F, Pavlou M et al (2014) A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 35:2010–2020. https://doi.org/10.1093/eurheartj/eht439

    Article  Google Scholar 

  20. Dewitt ES, Triedman JK, Cecchin F et al (2014) Time dependence of risks and benefits in pediatric primary prevention implantable cardioverter-defibrillator therapy. Circ Arrhythm Electrophysiol 7:1057–1063. https://doi.org/10.1161/CIRCEP.114.001569

    Article  PubMed  Google Scholar 

  21. Maurizi N, Passantino S, Spaziani G et al (2020) Long-term outcomes of pediatric-onset hypertrophic cardiomyopathy and age-specific risk factors for lethal arrhythmic events. JAMA Cardiol 3(6):520–525. https://doi.org/10.1001/jamacardio.2018.0789

    Article  Google Scholar 

  22. Pelliccia A, Fagard R, Bjørnstad HH et al (2005) Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the study group of sports cardiology of the working group of cardiac rehabilitation and exercise physiology and the working group of my. Eur Heart J 26(14):1422–1445. https://doi.org/10.1093/eurheartj/ehi325

    Article  PubMed  Google Scholar 

  23. Maron BJ, Udelson JE, Bonow RO et al (2015) Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis a stateme. Circulation 132:e273–e280. https://doi.org/10.1161/CIR.0000000000000239

    Article  PubMed  Google Scholar 

  24. Maron MS, Rowin EJ, Wessler BS et al (2019) Enhanced American college of cardiology/American heart association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy. JAMA Cardiol 4(7):644–657. https://doi.org/10.1001/jamacardio.2019.1391

    Article  PubMed  Google Scholar 

  25. Sharma S, Bs C, Elliott PM et al (2000) Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol 36(3):864–870. https://doi.org/10.1016/S0735-1097(00)00816-0

    Article  CAS  PubMed  Google Scholar 

  26. Pelliccia A, Lemme E, Maestrini V et al (2018) Does sport participation worsen the clinical course of hypertrophic cardiomyopathy? clinical outcome of hypertrophic cardiomyopathy in athletes. Circulation 137:531–533. https://doi.org/10.1016/j.jacc.2015.09.035.3

    Article  PubMed  Google Scholar 

  27. Christian S, Atallah J (2018) Physical activity restriction for children and adolescents diagnosed with an inherited arrhythmia or cardiomyopathy and its impact on body mass index. J Cardiovasc Electrophysiol 29:1648–1653. https://doi.org/10.1111/jce.13713

    Article  PubMed  Google Scholar 

  28. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G (2003) Does sports activity enhance the risk of sudden death in adolescents and young adults ? J Am Coll Cardiol 42(11):1959–1963. https://doi.org/10.1016/j.jacc.2003.03.002

    Article  PubMed  Google Scholar 

  29. Dias K, Link MS, Levine B (2018) Exercise training for patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 72(10):1157–1165. https://doi.org/10.1016/j.jacc.2018.06.054

    Article  PubMed  Google Scholar 

  30. Howden E, Sarma S, LAwley J et al (2018) Reversing the cardiac effects of sedentary aging in middle age-a randomized controlled trial: implications for heart failure prevention. Circulation 137:1549–1560. https://doi.org/10.1161/CIRCULATIONAHA.117.030617

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Jones S, Elliott PM, Sharma S, Mckenna WJ, Whipp BJ (1998) Cardiopulmonary responses to exercise in patients with hypertrophic cardiomyopathy. Heart 80:60–67

    Article  CAS  Google Scholar 

  32. Klempfner R, Kamerman T, Schwammenthal E et al (2015) Efficacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: results of a structured exercise training program in a cardiac rehabilitation center. Eur J Prev Cardiol 22(1):13–19. https://doi.org/10.1177/2047487313501277

    Article  PubMed  Google Scholar 

  33. Konhilas JP, Watson PA, Maass A et al (2006) Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy. Circ Res 98:540–548. https://doi.org/10.1161/01.RES.0000205766.97556.00

    Article  CAS  PubMed  Google Scholar 

  34. Maragiannis D, Alvarez PA, Ghosn MG et al (2018) Left ventricular function in patients with hypertrophic cardiomyopathy and its relation to myocardial fibrosis and exercise tolerance. Int J Cardiovasc Imaging 34(1):121–129. https://doi.org/10.1007/s10554-017-1214-z

    Article  PubMed  Google Scholar 

  35. Sheikh N, Papadakis M, Schnell F, Panoulas V, Malhotra A, Wilson M (2015) Clinical profile of athletes with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 8:1–9. https://doi.org/10.1161/CIRCIMAGING.114.003454

    Article  Google Scholar 

  36. Basu J, Malhotra A, Papadakis M (2020) Exercise and hypertrophic cardiomyopathy : two incompatible entities ? Clin Cardiol. https://doi.org/10.1002/clc.23343

    Article  PubMed  PubMed Central  Google Scholar 

  37. Saberi S, Day SM (2018) Exercise and hypertrophic cardiomyopathy: time for a change of heart. Circulation 137:419–421. https://doi.org/10.1161/CIRCULATIONAHA.117.029989

    Article  PubMed  Google Scholar 

  38. Dejgaard LA, Haland TF, Lie OH et al (2018) Vigorous exercise in patients with hypertrophic cardiomyopathy. Int J Cardiol 250:157–163. https://doi.org/10.1016/j.ijcard.2017.07.015

    Article  PubMed  Google Scholar 

  39. Sweeting J, Ingles J, Timperio A, Patterson J, Ball K, Semsarian C (2016) Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers. Open Hear 3:1–9. https://doi.org/10.1136/openhrt-2016-000484

    Article  Google Scholar 

  40. Shiroma EJ, Lee I (2010) Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation 122:743–752. https://doi.org/10.1161/CIRCULATIONAHA.109.914721

    Article  PubMed  Google Scholar 

  41. Reineck E, Rolston B, Bragg-gresham JL et al (2013) Physical activity and other health behaviors in adults with hypertrophic cardiomyopathy. Am J Cardiol 111(7):1034–1039. https://doi.org/10.1016/j.amjcard.2012.12.018

    Article  PubMed  Google Scholar 

  42. Saberi S, Wheeler M, Bragg-Gresham J et al (2017) Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: a randomized clinical trial. JAMA 317(13):1349–1357. https://doi.org/10.1001/jama.2017.2503

    Article  PubMed  PubMed Central  Google Scholar 

  43. Maron BJ, Rowin EJ, Casey SA, Garberich RF, Maron MS (2016) What do patients with hypertrophic cardiomyopathy die from? Am J Cardiol 117:434–435. https://doi.org/10.1016/j.amjcard.2015.11.013

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Emory University School of Medicine, Atlanta, USA

    Robert D. Whitehill, Michael Kelleman, Chad Mao, Peter Fischbach & Robert Campbell

  2. Department of Cardiology, Children’s Healthcare of Atlanta, Atlanta, USA

    Robert D. Whitehill, Michael Kelleman, Chad Mao, Peter Fischbach & Robert Campbell

  3. Department of Pediatrics, Oregon Health and Science University, Portland, USA

    Seshadri Balaji

  4. Division of Cardiology, Ann & Robert H. Lurie Children’s Hospital, Northwestern University Feinberg School of Medicine, Chicago, USA

    Stephanie F. Chandler

  5. Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, USA

    Dominic J. Abrams

Authors
  1. Robert D. Whitehill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seshadri Balaji
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Kelleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephanie F. Chandler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dominic J. Abrams
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chad Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Peter Fischbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Robert Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert D. Whitehill.

Ethics declarations

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 42 KB)

Supplementary file2 (DOCX 41 KB)

Supplementary file3 (DOCX 33 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Whitehill, R.D., Balaji, S., Kelleman, M. et al. Exercise Recommendations in Pediatric HCM: Variation and Influence of Provider Characteristics. Pediatr Cardiol 43, 132–141 (2022). https://doi.org/10.1007/s00246-021-02703-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-021-02703-0

Search

Navigation